Eli Lilly's Diabetes Drug Shows Statistical Reduction In Blood Sugar Levels In Children, Adolescents

Eli Lilly And Co's LLY DINAMO Phase 3 trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with Jardiance (empagliflozin) compared with placebo for children and adolescents with type 2 diabetes.
When Jardiance was added to other baseline treatments (diet, exercise, metformin and/or insulin), HbA1c was reduced by 0.84% compared with the placebo at week 26.
Related: Eli Lilly Is Best-In-Class Growth, Says Analyst While Initiating Coverage.
The overall safety data was generally consistent with previous findings in adults with type 2 diabetes, confirming the well-established safety profile of both Jardiance and Tradjenta.
A secondary endpoint from the trial showed that at week 26, Jardiance reduced fasting plasma glucose.
Reduction in HbA1c in participants treated with Tradjenta was not statistically significant when compared with placebo. A numerical reduction of 0.34% (P=0.2935) was observed.
Last month, Boehringer Ingelheim and Eli Lilly said Jardiance slowed the progression of chronic kidney disease.
The companies said the EMPA-KIDNEY phase 3 trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for chronic kidney disease.
Price Action: LLY shares are up 1.10% at $372.36 on the last check Wednesday.